Clinical Trial Search

Primary: Motor Reaction Time (MRT) (ms): Change From Baseline at Each Time Point During Acute Dosing Phase — 4.1; 0.7; -10.8 miliseconds

Primary: Cmax BIA 2-005 - the Maximum Plasma Concentration of BIA 2-005 — 7107.7; 10724.8; 13186.4; 6660.3 ng/mL

Primary: Incidence of Treatment-emergent AE's — 16 participants

Primary: 6 Minute Walk Test (Metres) — 54.3 metres

Primary: Number of Participants Who Experienced Dose Limited Toxicity in Combination Therapy of Nintedanib and Docetaxel — 0; 2; 0; 1 Participants

Primary: Maximum Measured Serum Concentration (Cmax) for Serum Deferiprone and Deferiprone 3-O-glucuronide — 7.406; 17.835; 27.749; 36.644 μg/mL

Primary: Cmax - the Maximum Plasma Concentration — 15809; 10496; 10364; 437 ng/mL

Primary: Change in Cocaine Use by Self Report — 72.2; 79.2; 91.1; 69.6 percentage of days abstinent

Primary: Cmax - Maximum Observed Plasma BIA 2-194 Concentration — 0.00; 8443; 10691; 10961 ng/mL

Primary: Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1 — 100; 0; 0; 11 percentage of participants

Primary: Cmax - Maximum Steady-state Plasma Concentration — 31652 ng/mL

Primary: Incidence of Solicited Reactions — 0; 0; 0 participants

Primary: Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞) — 183; 89.4 ng*h/mL — p=1.0000

Primary: Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞) — 38.6; 61.3 ng*h/mL — p=1.0000

Primary: mTBI Questionnaire — 5.38; 7.52 correct answers out of 10